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http://dxObjectives: Reinterventions after the Ross procedure are a concern for patients and treating physicians. The
scope of the present report was to provide an update on the reinterventions observed in the large patient popu-
lation of the German-Dutch Ross Registry.
Patients andMethods: From 1988 to 2011, 2023 patients (age, 39.05 16.5 years; male patients, 1502; adults,
1642) underwent a Ross procedure in 13 centers. The mean follow-up was 7.1  4.6 years (range, 0-22 years;
13,168 patient-years).
Results: In the adult population, 120 autograft reinterventions in 113 patients (1.03%/patient-year) and 76
homograft reinterventions in 67 patients (0.65%/patient-year) and, in the pediatric population, 14 autograft
reinterventions in 13 patients (0.91%/patient-year) and 42 homograft reinterventions in 31 patients (2.72%/pa-
tient-year) were observed. Of the autograft and homograft reinterventions, 17.9% and 21.2% were performed
because of endocarditis, respectively. The subcoronary technique in the adult population resulted in significantly
superior autograft durability (freedom from autograft reintervention: 97% at 10 years and 91% at 12 years;
P<.001). The root replacement technique without root reinforcement (hazard ratio, 2.4; 95% confidence inter-
val, 1.4-4.1) and the presence of pure aortic insufficiency preoperatively (hazard ratio, 2.3; 95% confidence in-
terval, 1.5-3.5) were statistically significant predictors for a shorter time to reoperation. The center volume had
a significant influence on the long-term results. The freedom from homograft reoperation for the adults and
pediatric population was 97% and 87% at 5 years and 93% and 79% at 12 years, respectively (P<.001),
with younger recipient and donor age being significant predictors of a shorter time to homograft reoperation.
Conclusions: The autograft principle remains a valid option for young patients requiring aortic valve replace-
ment. The risk of reoperation depends largely on the surgical technique used and the preoperative hemodynam-
ics. Center experience and expertise also influence the long-term results. Adequate endocarditis prophylaxis
might further reduce the need for reoperation. (J Thorac Cardiovasc Surg 2012;144:813-23)Although the Ross procedure has been shown to offer nu-
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ities, and normal aortic valve hemodynamics,1-10 the
incidence of reoperation remains a concern. Together with
the technical complexity of the procedure, the need for
reoperations, on the autograft, the homograft, or both,
has been the cornerstone of debate of whether the
Ross procedure should be performed, especially in adult
patients.
The aim of the present study was to present in detail the
incidence of, reasons for, outcomes of, and factors that in-
fluence, reoperation after the Ross procedure observed in
the multicenter German-Dutch Ross Registry. Although
a detailed analysis of the adult and pediatric populations
is presented, the main focus of the present study was the
adult patient. The information presented could facilitate
decision making when informing young patients with aortic
valve disease before surgical intervention and could
serve as a basis for comparing the outcomes after therdiovascular Surgery c Volume 144, Number 4 813
Abbreviations and Acronyms
SC ¼ subcoronary
RR ¼ root replacement without additional root
reinforcement
RRþR ¼ root replacement with additional root
reinforcement
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DRoss procedure with that of alternative therapeutic options
for the treatment of aortic valve disease.PATIENTS AND METHODS
The German-Dutch Ross Registry collects data from 13 departments of
cardiac surgery, retrospectively for 1988 to 2001 and prospectively from
2002 onward (clinical trial no. NCT00708409). For the purposes of the
present study, the study database was frozen in August 2011 and included
2023 patients.
The operating surgeon at each center determined the surgical technique
(subcoronary [SC] or root replacement with [RRþR] or without [RR] addi-
tional root reinforcement procedures). Reinforcement interventions in the
RRþR group were performed either in the annulus only (n ¼ 394), the
sinotubular junction only (n ¼ 35), or at both levels (n ¼ 214). A total of
30 patients who underwent the root inclusion (miniroot) techniquewere in-
cluded in the SC group to create a group with all native root-preserving pro-
cedures. The details of the operative techniques and the reasons for
including the root inclusion technique patients in the SC group have
been reported previously.1,2,6 All the patients provided informed consent;
the local ethics committee approved the study; all authors had full access
to, and take full responsibility for, the integrity of the data.
All indications for the primary operation and for all reoperations were in
accordance with the 2008 guidelines.11 Clinical follow-up examinations
were performed at discharge and yearly thereafter. The reporting and anal-
ysis of the outcomes and major adverse cardiac and cerebrovascular events
were according to published guidelines.12
The present report focused on the need for cardiac, valve-related reinter-
ventions on the autograft or homograft after the Ross procedure. Cardiac
nonvalvular, as well as cardiac, valvular, non–Ross-related interventions,
are not presented. Cases of pacemaker implantation within 14 days after
the Ross procedure were not included in the present study and have been
previously reported.1,6 A Ross reintervention was defined as any surgical
or interventional procedure performed after the initial Ross procedure on
the autograft or homograft. A Ross reoperation was defined as a surgical
session that included at least 1 Ross reintervention on the autograft or
homograft, or both (1, 1, and 2 reinterventions, respectively) and could
include concomitant interventions to other cardiac structures.
The adult and pediatric population of the Registry were analyzed and
reported separately. The cutoff point of 16 years was chosen to differentiate
the adult and pediatric populations, because at this age, the patients were
regarded from a surgical viewpoint as adults and the technical aspects of
the procedure were those of the adult population.
Frequencies are given as absolute numbers and percentages. Continuous
data are expressed as the mean  standard deviation. The actuarial esti-
mates of freedom from reoperation events were made using the Kaplan-
Meier method. The instantaneous risk of reoperation is presented as the
smoothed instantaneous probability that a patient will require reoperation
within the interval (t, tþ dt) provided the patient was not censored until
the beginning of t.13-15 To identify the predictive variables for a shorter
time to reoperation on the autograft or homograft, we performed
univariate analyses using the Cox proportional hazard regression model.
Multivariate Cox proportional hazard models were used to confirm814 The Journal of Thoracic and Cardiovascular Surgwhether significant (P < .10) univariate predictors persisted in the
presence of other preoperative variables. The following factors were
analyzed as potential risk factors for autograft or homograft reoperation:
age, year of surgery, gender, presence of co-morbidities (eg, diabetes, hy-
pertension, renal failure, coronary artery disease, pulmonary disease, pe-
ripheral vascular disease), previous cardiac surgery, preoperative
hemodynamics, aortic valvemorphology, center experience (number of op-
erated patients per center), year of surgery, and homograft donor parame-
ters (eg, diameter, donor recipient age and blood group mismatch).
Given the data obtained to date from the German-Dutch Ross Registry
and our understanding of the risk of autograft and homograft reintervention
that patients undergoing the Ross procedure face, we attempted to extrap-
olate the estimated risk of reoperation for a Ross patient up to 70 years of
age according to the patient’s age at the initial Ross procedure, taking into
consideration the probability of survival up to 70 years old. The survival of
the Ross patients was assumed to be similar to that of the German general
population (data available from: https://www.destatis.de), because several
studies have failed to show excess mortality for the Ross population com-
pared with that of the general population.3,6,7,15 For the calculation of the
estimated risk of reoperation with the SC and RR techniques, the
hazards for autograft and homograft reoperation were assumed to be
independent, and the Ross-related reoperation hazard rate was evaluated
as the sum of the hazard rate for the autograft and homograft reoperation
functions. The homograft hazard rate in the adults was assumed to be linear
(see Figure 2). For the SC technique, a constant autograft reoperation haz-
ard rate was assumed for the period after 17 years of follow-up
ðhSCðt  17Þ ¼ 0:014Þ. For the RR group, significant evidence was seen
for an increase in the autograft hazard rate with time (see Figure 3),1,6
and an exponential hazard rate was assumed hRRðtÞ ¼ 0:01þ 0:01e t5:9
(see Figure 3).RESULTS
The patient characteristics and operative data are
presented in Table 1. Completeness of follow-up for the
outcomes presented in the present study was 96%.
A detailed listing of the reoperations and reinterventions
observed in the total population, stratified by technique and
population subgroup, is presented in Table 2. The reopera-
tive mortality rate is also listed in Table 2.
The choice of autograft or homograft replacement
material used in the respective reinterventions is listed in
Table 3.
The actuarial estimates for freedom for autograft, homo-
graft, and combined reoperation for the subpopulations of
the present study are listed in Table 4. The survival esti-
mates for the adult and pediatric populations are also listed
in Table 4. No significant difference was seen between the
survival of the adult Ross population and that of the age-
and gender-matched general population (P ¼ .3). However,
the survival of the pediatric population was significantly in-
ferior to that of the age- and gender-matched general popu-
lation (P<.0001).
The results of the multivariate Cox proportional hazards
model for a shorter time to autograft and homograft
reoperation in the adult population are listed in Table 5.
Freedom from autograft, homograft, or combined reoper-
ation in the population groups and the technique subgroups
are displayed in Figures 1 to 5.ery c October 2012
TABLE 1. Patient characteristics and operative data
Total Adults Pediatric
Adults
SC RR RRþR
Patients (n) 2023 1760 263 771 346 643
Follow-up (y)
Mean 7.1 7.1 6.9 7 9.1 6.1
Range 0-22.4 0-22.4 0-21.8 0-18.5 0-22.4 0-15
Age (y) 39  16.5 43.7  12.0 8  5.2 45.2  11.3 37.6  12.6 45.1  11.3
Male gender 1502 (74%) 1315 (75%) 187 (71%) 585 (76%) 253 (73%) 477 (74%)
Age group (y)
<16 263 (13%) (0%) 263 (100%)
16-40 661 (33%) 661 (38%) 255 (33%) 198 (57%) 208 (33%)
41-60 1019 (50%) 1019 (58%) 470 (61%) 141 (41%) 408 (63%)
>60 80 (4%) 80 (4%) 46 (6%) 7 (2%) 27 (4%)
Predominant aortic hemodynamics
Regurgitation 469 (23%) 423 (24%) 46 (17%) 197 (26%) 87 (25%) 139 (22%)
Stenosis 457 (23%) 408 (23%) 49 (19%) 143 (19%) 79 (23%) 186 (29%)
Combined 1048 (52%) 894 (51%) 154 (59%) 419 (54%) 172 (50%) 303 (47%)
Aortic valve type
Bicuspid 1254 (62%) 1105 (63%) 149 (56%) 532 (69%) 189 (55%) 384 (60%)
Tricuspid 480 (24%) 410 (23%) 70 (27%) 170 (22%) 110 (32%) 130 (20%)
Other 175 (9%) 157 (9%) 18 (7%) 34 (4%) 23 (7%) 100 (16%)
Unknown 111 (5%) 85 (5%) 26 (10%) 35 (5%) 22 (6%) 28 (4%)
Atrial fibrillation 16 (1%) 16 (1%) 0 (0%) 11 (1%) 2 (1%) 3 (0%)
Concomitant procedures (n)
Total 884 (44%) 813 (46%) 71 (27%) 333 (43%) 99 (29%) 381 (59%)
CABG 102 (5%) 100 (6%) 2 (1%) 30 (4%) 19 (5%) 51 (8%)
Previous cardiac interventions (n) 299 (15%) 158 (9%) 141 (54%) 40 (5%) 40 (12%) 57 (9%)
Circulatory arrest
Patients (n) 106 (5%) 97 (6%) 9 (3%) 62 (8%) 62 (18%) 30 (5%)
Mean  SD 18.2  10.8 17.4  9 39.7  29.3 17.9  4 17.9  4 13.2  4.6
Range 2-72 2-64 15-72 11-33 11-33 3-23
CPB time (min)
Mean  SD 189.1  47.6 191.2  45.6 175.7  57.1 211  35.2 211  35.2 170.7  41.9
Range 61-685 71-685 61-495 71-433 71-433 95-482
Cross-clamp time (min)
Mean  SD 146.2  36.1 150.4  34.9 119.7  31.8 172.2  34.1 172.2  34.1 135.1  24.9
Range 17-293 38-293 17-265 43-293 43-293 79-258
In-hospital (<30 d) mortality 29 (1.4%) 20 (1.1%) 9 (3.4%) 8 (1%) 2 (0.6%) 10 (1.6%)
CABG,Coronary artery bypass grafting;CPB, cardiopulmonary bypass; RR, root replacement without additional root reinforcement; RRþR, root replacement with additional root
reinforcement; SC, subcoronary; SD, standard deviation. n ¼ Number of patients.
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DDISCUSSION
The main scope of the present study was to provide a de-
tailed presentation of the reasons, incidence, results, and
outcomes of reoperations on the autograft or homograft af-
ter the Ross procedure in the adult and pediatric populations
of the German-Dutch Ross Registry. The incidence of other
major adverse cardiac and cerebrovascular events has been
previously reported.6 The information provided in the pres-
ent study might facilitate patient–physician discussions be-
fore aortic valve interventions and outline patient
expectations after the Ross procedure regarding the proba-
bility, incidence, and outcomes of reoperations. The present
results could also serve as a basis for a comparison of the
outcomes after the Ross procedure with those after otherThe Journal of Thoracic and Canovel or conventional therapeutic options for the treatment
of aortic valve disease.
Although the first Ross procedure was performed as
an SC transplant,16 the technical complexity of this
procedure eventually led to the development of the RR
technique, which provided, at least for the early to mid-
term, satisfactory results.17 The initial enthusiasm for
the RR Ross procedure soon waned, after several reports
of the increased incidence of reoperations because of
autograft dilatation starting 7 to 10 years after the initial
procedure.18-25 Research on the modes of failure of the
pulmonary autograft has shown a technique-specific pat-
tern of autograft failure.1 In the RR technique, the main
mode of autograft failure seems to be nonstructural valverdiovascular Surgery c Volume 144, Number 4 815
TABLE 2. Reinterventions observed in German-Dutch Ross Registry
Technique
TotalRR RRþR SC
Adults
Patients with Ross-related reoperation (% of total) 64 (18.5%) 39 (6.1%) 53 (6.9%) 156 (8.9%)
Follow-up (y)
Mean  SD 9.1  5.4 6.1  3.9 7  4.3 7.1  4.5
Range 0-22.4 0-15 0-18.5 0-22.4
Cumulative follow-up (pt-y) 2925.3 3481.7 5218.7 11,625.7
Ross-related reoperations 69 43 62 174
Reoperation mortality (n) 0 1 5 6
Ross-related reinterventions 79 45 72 196
Reoperation type
Autograft 44 27 27 98
Homograft 15 14 25 54
Combined 10 2 10 22
Autograft reinterventions 54 29 37 120
Endocarditis 1 11 11 23
SVD 4 7 20 31
NSVD 49 10 6 65
Technical 1 1 0 2
Homograft reinterventions 76
SVD
Stenosis 44
Regurgitation 10
NSVD 6
Endocarditis 16
Pediatric
Patients with Ross-related reoperation (% of total) 28 (16.6%) 7 (18.9%) 6 (10.5%) 41 (15.6%)
Follow-up (y)
Mean  SD 6.4  5.7 8.5  2.8 7.2  4.3 6.9  5.2
Range 0-21.8 0.2-13.5 0-16.4 0-21.8
Cumulative follow-up (pt-y) 933.1 306.4 303.3 1542.7
Ross-related reoperations 37 8 9 54
Reoperation mortality (n) 0 0 0 0
Ross-related reinterventions 38 9 9 56
Reoperation type
Autograft 9 2 1 12
Homograft 27 5 8 40
Combined 1 1 0 2
Autograft reintervention 10 3 1 14
NSVD 10 3 0 13
Endocarditis 0 0 1 1
Homograft reinterventions 42
SVD
Stenosis 25
Regurgitation 7
NSVD 1
Endocarditis 9
NSVD, Nonstructural valve deterioration; pt-y, patient-year; RR, root replacement without additional root reinforcement; RRþR, root replacement with additional root reinforce-
ment; SC, subcoronary; SVD, structural valve deterioration; SD, standard deviation.
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unsupported pulmonary root under systemic pressure,
leading to progressive loss of valve coaptation and the de-
velopment of autograft insufficiency. However, when the
autograft is implanted as an SC transplant, the main cause816 The Journal of Thoracic and Cardiovascular Surgof failure is leaflet-related degeneration (structural valve
deterioration; Table 2).
Although some prominent series have been published
with excellent results after the RR Ross procedure,23,25,26
the high failure rate after the first decade has initiatedery c October 2012
TABLE 3. Choice of replacement material at reintervention
Biologic Homograft Mechanical Repair Valve sparing Catheter Unknown/not coded
Adults
Autograft (n) 26 8 45 19 7 1 14
Age at reoperation (y)
Mean  SD 47.3  12.9 38.5  12.5 32.0  12.5 44.0  10.8 39.7  9.79
Range 21.9-64.9 18.9-52.0 16.2-66.0 20.2-58.3 23.4-50.9
RR 5 4 35 3 1 1 5
RRþR 9 3 1 9 6 1
SC 12 1 9 7 8
Homograft 6 39 1 2 16 12
Pediatric
Autograft 0 4 3 2 2 0 3
RR 3 3 1 3
RRþR 1 1 1
SC 1
Homograft 1 19 2 3 11 6
The decision for the type of prosthesis at reoperation was the result of a thorough informed consent process after taking into consideration the recommendations and patient-
specific needs and wishes. RR, Root replacement without additional root reinforcement; RRþR, root replacement with additional root reinforcement; SC, subcoronary; SD, stan-
dard deviation.
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a search for technical modifications to prevent root
dilatation.1,6-8,17,27,28 During the past decade, several
groups have reported satisfactory results with the
modified RR Ross procedure, using autograft root
reinforcement with various techniques and materials in an
attempt to stabilize the tissue and the areas of the aortic
root that have been shown to dilate and result in
progressive autograft insufficiency late after the Ross
procedure.1,17,27,28 This change has also been observed in
the German-Dutch Ross Registry, with most active centers
having switched now to either the SC technique or to RR
with aggressive reinforcement of the autograft annulus or
sinotubular junction, or both.1 A small increase in the risk
of reoperation in the RRþR group after the first decade
has been observed (Figure 3). However, to date, no statisti-
cally significant difference in the freedom from autograft
reoperation can be observed between the RRþR and SC
groups. Because RRþR is a relatively new technique, only
a few (<6%) of patients have completed a follow-up period
of longer than 12 years. Therefore, reliable conclusions
about the second decade could not be made for the RRþR
group.
Endocarditis remains a significant cause of reoperation
after the Ross procedure. Although it was initially believed
that the Ross procedure, by using only biologic (autologous
and allogenic) material, might be resistant to postoperative
endocarditis, data from the German-Dutch Ross registry
have shown that almost 20% of all interventions on the au-
tograft or homograft were performed because of endocardi-
tis (Table 2). This should be of interest to the treating
physician and for the follow-up of Ross patients, because
aggressive endocarditis prophylaxis could lead to a reduc-
tion in the incidence of endocarditis and, thus, the needThe Journal of Thoracic and Cafor reoperations. The understanding that endocarditis can
occur in patients with autologous and allograft material, to-
gether with a high clinical suspicion, is required to diagnose
nonfulminant autograft or homograft endocarditis and pre-
vent valve deterioration. This is especially important for
Ross patients, because 2 valves are at risk and because the
latest guidelines are more restrictive regarding the use of
antibiotic prophylaxis.29
Several groups have demonstrated that patients with pure
aortic insufficiency with or without aortic dilatation seem
to have a much greater incidence of autograft deteriora-
tion.30-36 Although the data from the German-Dutch
Ross Registry have shown that although pure aortic insuffi-
ciency is an independent predictor for a shorter time to
reoperation, this effect (Table 5) appears to be milder than
that reported in other series.33,35,36 Also, its effect seems
to be more pronounced with the RR technique without
active reinforcement. Although many patients with pure
aortic insufficiency currently undergo aortic valve
reconstruction, we believe that aortic insufficiency should
not be regarded as a contraindication to the Ross
procedure. Similarly, the presence of a bicuspid aortic
valve did not have any influence on the incidence of
autograft reoperation.
In the pediatric population, the effect of the surgical tech-
nique on autograft durability was less pronounced. Auto-
graft reoperations in the first decade were rare
(Figure 1)37 but could become necessary after the first de-
cade. Most reoperations and reinterventions in the pediatric
population were for homograft deterioration (Figure 2 and
Table 2).38 Also, younger homograft donor and recipient
age appeared to lead to significantly inferior homograft du-
rability (Table 5). Catheter reinterventions on the homograft
might reduce the need for conventional reoperationrdiovascular Surgery c Volume 144, Number 4 817
TABLE 4. Actuarial estimates for freedom from autograft,
homograft, or any Ross reintervention (with and without
endocarditis) and survival estimates in adult and pediatric population
Variable 5 y 12 y
Freedom from reoperation
Endocarditis included
Autograft
Adult
SC 97% (96-98) 91% (88-95)
RR 97% (95-99) 82% (76-88)
RRþR 96% (94-98) 91% (86-96)
Pediatric 98% (96-100) 95% (91-99)
Homograft
Adult 97% (97-98) 93% (91-95)
Pediatric 87% (82-92) 79% (72-87)
Combined
Adult
SC 95% (94-97) 88% (84-92)
RR 95% (92-97) 77% (71-83)
RRþR 94% (92-96) 87% (81-93)
Pediatric 86% (81-91) 76% (69-84)
Endocarditis excluded
Autograft
Adult
SC 98% (97-99) 94% (91-97)
RR 97% (95-99) 82% (76-88)
RRþR 98% (96-99) 93% (88-98)
Pediatric 98% (96-100) 95% (91-99)
Homograft
Adult 98% (97-99) 95% (93-96)
Pediatric 90% (85-94) 83% (90-76)
Combined
Adult
SC 97% (95-98) 91% (87-95)
RR 95% (92-97) 78% (72-84)
RRþR 96% (94-98) 90% (84-95)
Pediatric 89% (84-94) 80% (74-88)
Survival
Adult 98% (97-99) 93% (91-95)
Pediatric 97% (94-99) 95% (91-99)
Data in parentheses are 95% confidence intervals. RR, Root replacement without ad-
ditional root reinforcement; RRþR, root replacement with additional root reinforce-
ment; SC, subcoronary.
TABLE 5. Multivariate Cox proportional hazard model for shorter
time to autograft or homograft reoperation in adult population
Variable HR 95% CI P value
Autograft
Technique
SC Baseline
RRþR 1.4 0.8-2.3 .25
RR 2.4 1.4-4.1 .001
Center volume 0.998/patient 0.997-0.999 .001
Preoperative hemodynamics
Pure aortic regurgitation 2.3 1.5-3.5 <.001
Homograft
Patient age group (y)
<16 5.1 2.1-12.4 <.001
16-40 2.2 0.9-5.0 .08
41-60 Baseline
>60 0.9-5.0 .08
Donor age (y) 0.975 0.96-0.99 <.001
CI, Confidence interval; HR, hazard ratio; RR, root replacement without additional
root reinforcement; RRþR, root replacement with additional root reinforcement;
SC, subcoronary.
FIGURE 1. Freedom from autograft reintervention in the pediatric and
adult (all techniques) population.
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therapeutic option remains unknown.
As with any operation, the major determinants of the op-
erative outcome include not only the type and complexity of
the operation itself, but also the status of the patient at
surgery. During the 224 reoperations observed in the
German-Dutch Ross Registry, 6 patients died of postopera-
tive complications (2.6%). This low reoperative mortality
rate has also been observed by other groups.39-43
However, it is important to note that all these patients
presented with a critical status (5 patients because of
endocarditis and 1 patient for technical reasons) requiring
either urgent or emergency surgery. No reoperative818 The Journal of Thoracic and Cardiovascular Surgmortality was observed in the patients presenting or
scheduled for an elective reoperation.
In the young patient requiring aortic valve surgery,
the lifetime risk of valve-related complications with me-
chanical valves is neither 0% nor rare.44-46 If the Ross
procedure manages to bridge the young patient with aortic
valve disease from an age when a conventional biologic
solution is questionable (age, 20-60 years) to an age at
which a biologic or even transcatheter (age,>65-70 years)
solution is feasible, this, we believe, also constitutes
a success of the Ross procedure. However, even when anery c October 2012
FIGURE 2. Freedom from homograft reintervention in the pediatric and
adult population.
FIGURE 4. Freedom from autograft or homograft reintervention in the
adult population stratified by the operative technique. RR, Root replace-
ment without additional root reinforcement; RRþR, root replacement
with additional root reinforcement; SC, subcoronary.
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cases, the autograft can be either repaired or spared
(Table 3), thus retaining some of the benefits the pulmonary
autograft has to offer. Elective reoperation in the case of au-
tograft or homograft deterioration can be performed with re-
markable safety in experienced centers. Also, catheter
interventions will probably reduce the incidence and the
need for open conventional procedures further.FIGURE 3. Freedom from autograft reintervention in the adult population
stratified by the operative technique. RR, Root replacement without addi-
tional root reinforcement; RRþR, root replacement with additional root re-
inforcement; SC, subcoronary.
The Journal of Thoracic and CaDespite all therapeutic options and modalities, even
today, aortic valve replacement, remains a palliative treat-
ment. Mechanical and biologic prostheses bring advantages
and disadvantages that the patient and physician should
weigh carefully before making an important, informed
decision. Eventually, patients requiring aortic valve re-
placement face some risk of procedural or postoperative
valve-related complications. From the view of the treatingFIGURE 5. Freedom from autograft or homograft reintervention in the
pediatric population.
rdiovascular Surgery c Volume 144, Number 4 819
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risk avoidance or risk intolerance, might deny a great pro-
portion of young patients with aortic valve disease all the
benefits the Ross procedure has to offer.47,48FIGURE 6. Estimation of the probability of autograft or homograft rein-
tervention until 70 years of age according to the age at the Ross procedure
for patients treated with the subcoronary (SC) and root replacement (RR)
techniques.Study Limitations
The present study is a retrospective analysis of an ongo-
ing nonrandomized registry. The intention of the surgeon
when performing reinforcement was either to treat an un-
derlying pathology or to prophylactically stabilize key ele-
ments of the aortic root to prevent dilatation. For the
estimation of the probability of reoperation to the age of
70 years, the risk of autograft or homograft reoperation until
age 70 years was extrapolated from the data obtained to
date. The survival of the Ross patients was assumed to be
comparable to that of the general population. Although ev-
idence has shown that this holds true for the first 2 decades
after the Ross procedure,3,6,7,15 it is unclear whether this
persists beyond that point. However if the survival of
Ross patients after the second decade is inferior to that of
the general population, the probability of reoperation
would have been even smaller owing to the competing
risk of death.49-51CONCLUSIONS
The present report has outlined the most frequently dis-
cussed complication after the Ross procedure, namely, the
need for reoperation. Although we see several reasons for
a focused presentation on the incidence of reoperation after
the Ross procedure, one should evaluate and weigh the need
for reoperations under the prism of their relative frequency
and against the many benefits the Ross procedure offers to
the patient. These benefits include survival comparable to
that of the general population, freedom from lifelong anti-
coagulation, a superior quality of life, unrestricted daily ac-
tivities, and normal aortic valve hemodynamics.3-7,10
According to our current knowledge and estimations, not
all Ross patients will require reoperation when treated
with the SC technique (Figure 6), which, at least in the pe-
riod of the present study, provided the most robust long-
term results.
The risk of reoperation after the Ross procedure depends
largely on the surgical technique used and the preoperative
hemodynamics. Also, significant research and technical
modifications have been successful in progressively reduc-
ing the need for reoperation, especially in centers with ex-
perience in the treatment of young patients with aortic
valve disease. Adequate endocarditis prophylaxis to prevent
autograft or homograft endocarditis and increased clinical
suspicion might reduce the need for reoperation further.
The Ross procedure remains a valid option with many ben-
efits and small risks for the young patient requiring aortic
valve replacement.820 The Journal of Thoracic and Cardiovascular SurgReferences
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Dr JosephA. Dearani (Rochester, Minn). I have no disclosures.
Congratulations on the remarkable results. One of our previous
AATS [American Association for Thoracic Surgery] presidents,
Dr Tirone David, has acknowledged in the literature that the
Ross procedure is a ‘‘complex operation and one should not be sur-
prised that reoperations are more complicated.’’ In contrast, stan-
dard aortic valve replacement is generally a straightforward
operation that most residents would be allowed to perform. The
Ross procedure in children is not controversial. In fact, it is the pro-
cedure of choice when aortic valve replacement is required. How-
ever, in adults, the low early mortality of isolated aortic valve
replacement and relative good durability of bioprostheses or low
incidence of thromboembolic complications with ‘‘point of
care’’ testing in mechanical valve replacements makes the Ross
procedure more controversial. My comments will focus on 3 as-
pects of your results in the adult age bracket, and I will ask 3 ques-
tions at the end.
First, at the initial glance, superior autograft durability with the
SC implantation techniquemight imply that this is the technique ofrdiovascular Surgery c Volume 144, Number 4 821
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ation of the results demonstrated a high early mortality of 8% to
9% for reoperation in this group. In addition, when reoperation
was necessary in the SC group, most required replacement and
none underwent valve-sparing root replacement. Thus, although
reoperation was less likely with the SC technique, the greater op-
erative mortality associated with reoperation might temper enthu-
siasm to apply it more frequently.
Second, the finding of the relatively high incidence of endocar-
ditis of either the autograft or homograft is eye opening, counter-
intuitive, and unexpected, particularly because some centers
believe the Ross is the preferred operation for the initial treatment
of aortic valve endocarditis. Although no obvious explanation is
present in your report, I wonder whether the homograft preserva-
tion and preparation techniques in Europe could have potentially
influenced the susceptibility to infection.
Finally, the cumulative number of reinterventions or reopera-
tion for any given patient in the Ross population can be numerous.
Your results will add to the abundant data reporting the reoperation
rates after the Ross procedure. However, the reoperation rates
alone do not reflect the valve disease that many Ross patients are
harboring but for which they have not yet required reoperation.
Although isolated biologic or mechanical aortic valve replace-
ment is not free of subsequent interventions, when they are re-
quired, it is more likely related to isolated aortic valve issues
and complexity, and the risk of reoperation is often less than that
after the Ross. With that said, your report today of low early mor-
tality for the Ross procedure and low early mortality with reoper-
ation and the excellent late survival make a persuasive argument
for more liberal application of the Ross procedure in the young
and in middle-age adults, particularly when surgical services are
centralized.
My questions are the following. First, what is the Ross implan-
tation technique of choice? Second, do you believe the Ross pro-
cedure is a legitimate contender in the current era of excellent
outcomes with minimally invasive aortic valve replacement? Fi-
nally, although not the focus of your review, do you have any echo-
cardiographic data about autograft or homograft abnormalities in
patients who are ‘‘on the way’’ to reoperation?
Thank you to the Association for the privilege of this discussion
and congratulations on the remarkable results.
Dr Charitos. Thank you very much. These are very pertinent
questions. The Ross technique of choice is more or less a matter
of debate. Obviously I am biased toward the SC technique. I
come from Luebeck; Professor Sievers has probably the most ex-
tensive experience with the SC technique. I do believe that the
Ross procedure should be performed with the SC technique.
This seems logical. We have now more than 600 patients with
a complete follow-up rate of 98%. We know exactly what happens
to all our patients. The SC technique seems to be technically more
demanding; one should know which items one should pay special
attention to and which to avoid during the procedure, but the SC
technique does provide more robust results.
Some surgeons might prefer other techniques, such as the root
replacement technique or root replacement with reinforcement.
Some prominent root replacement series have been published,
with very good results. However, in general and in the multicenter
Ross registry, the root replacement technique without822 The Journal of Thoracic and Cardiovascular Surgreinforcement has generally underperformed, and I think the
data are consistent that the SC provides the best and the most ro-
bust results in the long term.
Your second question has to do with minimally invasive aortic
valve replacement in this era. Minimally invasive aortic valve re-
placement does not offer many advantages for the 20-, 30-, or
35-year-old patient. Perhaps cosmetically; however, the problem
of valve choice in the patient who is 20 or 25 years old does not
depend on the type of surgical access.
The problem these patients face is mainly from the type of pros-
thesis. If one implants a biologic valve in a 20-year-old patient, one
will probably see the patient again in 5 to 7 years. However; a me-
chanical valve will change the patient’s lifestyle, and the patient
will face a certain lifetime risk of significant complications.
Thus, the type of surgical access for aortic valve replacement in
young patients I do not believe has a major effect for a young pa-
tient with aortic valve disease, other than, perhaps, cosmetic
implications.
And the third question?
Dr Dearani.Whether you have any information about echocar-
diographic data on the hemodynamic abnormalities in patients that
many have but who have not yet required reoperation.
Dr Charitos. This is also a very pertinent question. We do have
echocardiographic data. There are patients who have some auto-
graft or homograft dysfunction that might eventually require reop-
eration but who have, at least for now, not reached the indications
for reoperation. The indications for reoperation are much more
clear with the autograft and slightly more hazy for the homograft,
but certainly we had patients in the study with valve dysfunction at
risk of reoperation.
Dr Azhar Hossain (Miami, Fla). My question is regarding the
bicuspid valve in the young adult, say 20 years old, with severe re-
gurgitation.Would you recommend the Ross procedure for that pa-
tient? If so, what procedure would you choose, the classic Ross,
which is the SC, or the root replacement?
Dr Charitos. A bicuspid aortic valve is not a contraindication
for the Ross procedure. Patients with pure aortic regurgitation do
have a greater risk of reoperation; the hazard ratio is about 2.4
to 2.9. But we do not consider patients with a bicuspid aortic valve
to have a contraindication to the Ross procedure. Currently, I think
the tendency is to repair these valves, but certainly we do not re-
gard a bicuspid aortic valve as a contraindication for the Ross
procedure.
The choice of procedure is more or less surgeon specific. We
have found that if a center uses 1 specific technique, it usually
sticks to that technique. Whether the surgeon will perform addi-
tional interventions, for example, to stabilize the aortic annulus
or the sinotubular junction in patients with pure aortic insuffi-
ciency who have some malformation of the aortic root, this is
something one must decide in the operating room. But the choice
of technique is mostly surgeon specific.
Dr Hossain. Thus, in other words, you are not concerned that in
a bicuspid aortic valve, there is additional risk of root dilatation if
you do a root replacement as opposed to an SC procedure?
Dr Charitos. No. We have extensively studied the effects
of bicuspid aortic valve in terms of aortic insufficiency and dilata-
tion of the aortic root. We published these findings about 3 or 4
years ago. We have found no clinically significant difference inery c October 2012
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patients with a bicuspid aortic valve, irrespective of the technique.
Dr Hossain. I was referring to the pulmonary autograft that you
are going to use in the aortic position. That has the same disease as
the native aortic root, which has been reported by many well-pub-
lished investigators. Thus, if you use a pulmonary autograft, which
has a tendency to undergo dilatation, would you still use root re-
placement, as opposed to the SC, in a Ross procedure, which is
the classic Ross?
Dr Charitos. I do not think there is much evidence that the pul-
monary autograft in the aortic position in a patient with a bicuspid
valve has a greater failure rate. There is only 1 report from the team
of Tirone David stating that in some patients with bicuspid aortic
valves there are some histologic abnormalities, but that is a very
long way to proving that if this patient has a pulmonary autograft
in the bicuspid aortic valve position, that the autograft will fail. If
one wants to determine whether in a patient with bicuspid aortic
valve the autograft fails to a greater extent, one must investigate
exactly that assumption. One cannot state that because we have
seen some histologic abnormalities in the pulmonary valve of
some bicuspid aortic valve patients, then implanting this pulmo-
nary autograft in the aortic position would be the cause of the fail-
ure. That is a very big leap.
We have extensively analyzed the effect of bicuspid valves and
we have seen no clinically significant influence of the bicuspid aor-
tic valve on the durability of the autograft.
Dr Andre Vincentelli (Lille, France). Congratulations for your
outstanding series. What was the proportion of patients receiving
the SC technique coming from Leubeck in your series?
Dr Charitos. I think I can say we contributed most of the pa-
tients treated with the SC technique. From the 750 patients in
the Ross registry treated with the SC technique, about 580 were
from Leubeck.
Dr Vincentelli. This experience seems to be quite unique in
Leubeck and the very good results with the SC technique that
you have reported remain hardly reproducible elsewhere. In our
series of 394 patients undergoing a Ross operation, we have
used the modified root inclusion with a Dacron Valsalva prostheses
in 69 patients since 2003. We had no reoperation with this tech-
nique that has become routinely used since April 2010 in our insti-
tution. Do you have such experience?
Dr Charitos.We have few patients with Dacron root inclusion
and 30 patients with the miniroot inclusion technique in the RossThe Journal of Thoracic and Caregistry. That was too small a population to analyze it separately.
Thus, we included the miniroot inclusion patients with the SC pa-
tients. Most of these patients with the SC technique were patients
in whom the noncoronary sinus was preserved. So it could be
considered is a root-preserving technique; the SC technique or
the miniroot technique is a type of native root-preserving
technique.
DrNicholas T. Kouchoukos (St. Louis, Mo). Just a follow-up to
Dr Dearani’s questions. Regarding the SC technique, you have
a large experience with this, and it is fairly clear that the failure
rates will be different between the SC technique and the root re-
placement technique, and he asked you about echocardiographic
follow-up. Have you seen increases in the degree of aortic regurgi-
tation with the SC technique in patients who have not yet required
reoperation, because this is an important consideration. My second
question relates to the techniques of preservation of the homograft.
Were different techniques used among the different institutions?
Were these available commercially or were they prepared in
your own hospital?
Dr Charitos. Regarding your first question, we recently pub-
lished our experience with 200 patients with more than 10 years
of follow-up, and we had complete echocardiographic data avail-
able. We follow-up every patient; we examine every patient, every
year. We have a complete follow-up rate of more than 98% in Lue-
beck, so we know exactly what happens to the patients.
In the SC technique, we have not seen this gradual increase in
the dimensions and aortic regurgitation one sees with the root re-
placement technique. When the SC technique fails, it is usually
abrupt and mostly due to isolated leaflet problems, cusp prolapse
or cusp tear, or endocarditis. Nevertheless, there are few patients
with moderate aortic regurgitation who might may require reoper-
ation in the future.
Regarding your second question, the evaluation of the homo-
graft is a very complex topic. There are many factors that could po-
tentially have an influence. The factors we have presented were
factors influencing, not the function of the homograft, but the in-
cidence of reoperation as an event. Drs Mokhles and Takkenberg
are analyzing the homograft data with the cooperation of Dr Black-
stone. We hope we will have some high-quality data and results on
the durability of the homograft and homograft function and the risk
for deterioration within this year.
But I just want to say that the evaluation of the homograft is
a very, very complex topic.rdiovascular Surgery c Volume 144, Number 4 823
